Background: Emergence of Multidrug resistant Tuberculosis (MDRTB) has become a significant obstacle for Tuberculosis (TB) control. Rifampicin (RIF) resistance is important indicator of MDRTB. Rapid simultaneous detection of Mycobacterium Tuberculosis (MTB) and RIF resistance are very essential for effective disease management. CBNAAT (Cartridge Based Nucleic Acid Amplification Test) also known as Gene Xpert MTB/RIF assay is a novel diagnostic tool for detection of MTB and RIF resistance. Aims and Objectives: To study the usefulness of CBNAAT for rapid detection of MTB and RIF resistance in MDRTB suspected cases. Materials and Methods: 1002 sputum samples were collected retrospectively from MDRTB suspected cases including both new cases and previously treated cases. These were processed using Gene Xpert MTB/RIF assay. The results were statistically analyzed. Results: Out of 1002 sputum samples, Rifampicin resistance was detected in 202 (20.15%) samples and RIF sensitive was detected in 800 (79.84%) samples. Out of 800 rifampicin sensitive cases sputum smear positive in 443(55.37) and negative in 357(44.62). Out of 202 RIF resistant samples, sputum smear were positive in 127 (62.87%) cases and negative in 75 (37.12%) cases. Conclusions: Gene Xpert MTB/RIF assay is a good screening tool for diagnosis of MTB and detection of RIF’s resistance from MDRTB suspected cases within a shorter period.